JPS6234725B2 - - Google Patents
Info
- Publication number
- JPS6234725B2 JPS6234725B2 JP55008730A JP873080A JPS6234725B2 JP S6234725 B2 JPS6234725 B2 JP S6234725B2 JP 55008730 A JP55008730 A JP 55008730A JP 873080 A JP873080 A JP 873080A JP S6234725 B2 JPS6234725 B2 JP S6234725B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- antiviral agent
- staphylococcus
- pieces
- bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003443 antiviral agent Substances 0.000 claims description 14
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 241000191940 Staphylococcus Species 0.000 claims description 7
- 241000606768 Haemophilus influenzae Species 0.000 claims description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 6
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 3
- 241000588653 Neisseria Species 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 241000193996 Streptococcus pyogenes Species 0.000 claims 2
- 201000009240 nasopharyngitis Diseases 0.000 claims 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 description 13
- 102000014150 Interferons Human genes 0.000 description 7
- 108010050904 Interferons Proteins 0.000 description 7
- 229940079322 interferon Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 239000002799 interferon inducing agent Substances 0.000 description 2
- 239000006402 liver broth Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000001973 thioglycolate broth Substances 0.000 description 1
- 239000007143 thioglycolate medium Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
【発明の詳細な説明】
本発明は抗ウイルス剤に係り、殊に異種死菌体
混合物を有効成分とする抗ウイルス剤に係る。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an antiviral agent, and more particularly to an antiviral agent containing a mixture of killed cells of different species as an active ingredient.
抗ウイルス剤に関しては、化学療法剤の開発と
相俟つて精力的に研究が進められ、その結果現在
ではアマンタジン系、ウラシル系薬剤などが使用
されるに至つているが、これら薬剤の殆んどが高
い副作用を有していて長期連用に問題がありウイ
ルス性疾患の治療に必ずしも優れているとは謂い
難いものであつた。一方、近年に至りウイルス感
染やウイルス増殖を抑制する因子としてインター
フエロン（IF）が開発されたが、これは人血か
ら抽出されしかもウイルス性肝炎治療に際して患
者１人当りに必要な量のIFを得には人血100を
必要とすると謂われており、従つてIFは薬剤と
して工業生産されるに至つていない。 Research into antiviral drugs has been carried out vigorously in conjunction with the development of chemotherapy drugs, and as a result, amantadine-based and uracil-based drugs are now in use, but most of these drugs are However, it has high side effects and problems with long-term use, and it cannot be said that it is necessarily excellent in treating viral diseases. On the other hand, in recent years, interferon (IF) has been developed as a factor that suppresses viral infection and virus proliferation, but it is extracted from human blood, and the amount of IF required per patient is required for the treatment of viral hepatitis. It is said that 100% of human blood is required to obtain IF, so IF has not yet been industrially produced as a drug.
本出願人は、異種死菌体混合物、殊にヒトの上
気道常在菌である肺炎球菌と、溶血連鎖球菌と、
ブドウ球菌と、カタルナイセリアと、四連球菌
と、緑膿菌と、インフルエンザ菌との死菌体混合
物を有効成分として含有している抗腫瘍剤に関し
て特許出願（特願昭53−36662、特開昭54−
129117）しているが、当該抗腫瘍剤が抗ウイルス
剤としてウイルス性疾患の治療にも充分に利用可
能であることを見出し本発明を完成するに至つ
た。 The present applicant has developed a mixture of dead bacteria, particularly pneumococci, which are common bacteria in the upper respiratory tract of humans, and hemolytic streptococci,
A patent application was filed for an antitumor agent containing as an active ingredient a mixture of dead bacteria of Staphylococcus, Catharneisseria, TetraStreptococcus, Pseudomonas aeruginosa, and Haemophilus influenzae (Japanese Patent Application No. 53-36662, Showa 54-
129117), but the present invention was completed by discovering that the antitumor agent can be fully utilized as an antiviral agent for the treatment of viral diseases.
本発明による抗ウイルス剤の有効成分は前記特
開昭54−129117公報に開示のものと全く同一であ
り又本出願人により呼吸器疾患治療剤殊に気管支
喘息治療剤として「ブロンカスマベルナ」なる商
品名の下に市販されている薬剤の有効成分と同様
であるが、その製法及び使用法について念のため
述べれば次の通りである。 The active ingredient of the antiviral agent according to the present invention is exactly the same as that disclosed in the above-mentioned Japanese Patent Application Laid-Open No. 129117/1983, and the applicant has also designated it as ``Broncas Maverna'' as a therapeutic agent for respiratory diseases, especially as a therapeutic agent for bronchial asthma. Although the active ingredient is the same as that of the drug marketed under the trade name, the method for its production and use is as follows.
製 法 〔〕 継代培養 各種菌種につき下記要領で継代培養する。Manufacturing method [] Subculture Subculture each bacterial species as follows.
(a) 肺炎球菌については肝臓ブイヨンで静置培
養する。 (a) For pneumococci, culture them statically in liver broth.
(b) ブドウ球菌、カタルナイセリア、四連球
菌、緑膿菌、インフルエンザ菌及び肺炎桿菌
についてはそれぞれ振盪培養し、純粋性を顕
微鏡にて検査する。 (b) Staphylococcus, Catalneisseria, Tetraphyllococcus, Pseudomonas aeruginosa, Haemophilus influenzae, and Klebsiella pneumoniae are each cultured with shaking, and their purity is examined using a microscope.
(c) 溶血連鎖球菌についてはチオグリコール酸
塩ブイヨンで静置培養する。 (c) For hemolytic streptococci, culture them statically in thioglycolate broth.
〔〕 培養
継代培養で得た各菌種につき純粋性及び抗原
性を検査した後に次の培地に菌を移植して後培
養を行なう。[]Culture After testing the purity and antigenicity of each bacterial species obtained through subculture, the bacteria are transferred to the next medium for post-culture.
(a) 肺炎球菌
ブドウ糖を加えた肝臓ブイヨンで静置培養
(b) ブドウ球菌、四連球菌、緑膿菌及び肺炎桿
菌
それぞれカゼイン水解物をベースとする液
体培地で通気性タンク培養
(c) カタルナイセリア
コーヘン・ホウイーラーの液体培地で通気
性タンク培養
(d) インフルエンザ菌
ホルトの液体培地で通気性タンク培養
(e) 溶血連鎖球菌
カゼイン水解物をベースとする液体培地で
通気せずにタンク培養
〔〕 採取菌の調製
菌の原形質が凝固したり、又菌の抗原物質が
溶出しないように特に留意しつつ次の操作を行
なう。 (a) Streptococcus pneumoniae Static culture in liver broth supplemented with glucose (b) Staphylococcus, Tetraphylococcus, Pseudomonas aeruginosa and Klebsiella pneumoniae each cultured in an aerated tank in a liquid medium based on casein hydrolyzate (c) Catarrhea Neisseria: Cultured in an aerated tank in Cohen-Wheeler's liquid medium (d) Haemophilus influenzae: Cultured in an aerated tank in Holt's liquid medium (e) Hemolytic Streptococcus: Cultured in a tank without aeration in a liquid medium based on casein hydrolyzate [ ] Preparation of collected bacteria Carry out the following operations, paying special attention to prevent the protoplasm of the bacteria from coagulating or eluting antigenic substances from the bacteria.
(a) 肺炎球菌以外の各菌については静止期に菌
を採取し、その純粋性を顕微鏡にて検査した
後に、比濁法により菌数を計算し、次いで60
℃に於て60分間維持して殺菌する。38w／ｗ
％のホルマリンを0.4v／ｖ％割合で添加して
滅菌する。然る後、遠心分離して上清を棄却
し沈渣のみを集めて洗浄し、生理食塩水を加
えてこれに懸濁せしめ死菌体懸濁原液とす
る。 (a) For each bacteria other than Streptococcus pneumoniae, collect the bacteria during the stationary phase, examine its purity under a microscope, calculate the number of bacteria using turbidimetry, and then
Sterilize by keeping at ℃ for 60 minutes. 38w/w
% formalin at a ratio of 0.4v/v% to sterilize. Thereafter, it is centrifuged, the supernatant is discarded, only the precipitate is collected and washed, and physiological saline is added and suspended therein to obtain a stock suspension of dead bacteria.
(b) 肺炎球菌については既述の後培養のための
移殖後約24時間を経過した後に菌を採取し、
(a)項と同様に処理して死菌体懸濁原液とす
る。 (b) For pneumococci, collect bacteria approximately 24 hours after transfer for post-culture as described above,
Process in the same manner as in section (a) to obtain a suspension of dead bacteria.
〔〕 無菌試験
各菌種の懸濁原液につきそれぞれ下記要領で
培養試験を行ない無菌状態であることを確認す
る。[] Sterility test Perform a culture test on each suspension of each bacterial species as follows to confirm that it is sterile.
(a) チオグリコール酸塩培地で10日間培養（培
養温度32℃）
(b) ペプトン／ブドウ糖培地で10日間培養（培
養温度32℃）
(c) ザブロー培地で10日間培養（培養温度20〜
25℃）
〔〕 原液の混合
無菌試験を経た原液（各原液は各々単一菌種
の死菌体を含有している）相互を無菌的操作の
下に撹拌器付タンク内で混合する。 (a) Cultured in thioglycolate medium for 10 days (culture temperature 32℃) (b) Cultured in peptone/glucose medium for 10 days (culture temperature 32℃) (c) Cultured in Zabro medium for 10 days (culture temperature 20~
25℃) [] Mixing of stock solutions Mix the stock solutions that have passed the sterility test (each stock solution contains killed cells of a single bacterial species) in a tank with an agitator under aseptic conditions.
使用法
注射液となされる場合には、原液混合物に防
腐剤としてフエノールが0.4w／ｗ％の割合で
添加混合され、次いでアンプルに１ml宛充填さ
れた後にアンプルが封緘される。注射液は１ml
中に各菌種の死菌体を例えば次の如く含有して
いる。Usage When making an injection solution, phenol is added as a preservative to the stock solution mixture at a ratio of 0.4 w/w%, and then 1 ml is filled into an ampoule, and the ampoule is sealed. 1ml of injection solution
It contains dead bacterial bodies of each bacterial species as follows, for example.
肺炎球菌 50×106個
溶血連鎖球菌 40×106個
ブドウ球菌 500×106個
カタルナイセリア 60×106個
四連球菌 20×106個
緑膿菌 250×106個
肺炎桿菌 40×106個
インフルエンザ菌 40×106個
本発明による抗ウイルス剤の生物活性を確認す
るためにvesicular stomatitis virus（USV、
Indiana strain）の細胞変性抑制試験によるイン
ターフエロン様物質誘起実験、抗癌作用実験及び
毒性試験を下記要領で行なつた処下記の結果が得
られた。 Pneumococcus 50×10 6 pcs Hemolytic Streptococcus 40×10 6 pcs Staphylococcus 500×10 6 pcs Catalneisseria 60×10 6 pcs Tetrastreptococcus 20×10 6 pcs Pseudomonas aeruginosa 250×10 6 pcs Klebsiella pneumoniae 40×10 6 Haemophilus influenzae 40×10 6 To confirm the biological activity of the antiviral agent according to the present invention, vesicular stomatitis virus (USV,
An interferon-like substance induction experiment, an anticancer effect experiment, and a toxicity test using a cell degeneration inhibition test (Indiana strain) were conducted in the manner described below, and the following results were obtained.
１ インターフエロン様物質誘起実験
(a) 使用動物
ddYマウス、雄、10週令、体重40ｇ前後、
１群 ４匹
(b) 本発明による抗ウイルス剤、投与量及び投
与経路
抗ウイルス剤
前記「使用法」の項に記載の注射液
投与量
５ml／Kg各１回
投与経路
腹腔内（i.p.）、
皮下注（s.c.）及び
静脈内（i.v.）
(c) 実験方法
マウスを４群に分け、内１群を対照とし他
の３群の各群については投与経路に従い本発
明製剤を注射投与し20時間後に対照も含めて
各マウスから採血する。分離した血清のイン
ターフエロン様活性をフインター（Finter
N.B.）等の方法〔The Assay and
Standerdization of Interferon and
Interferon Inducers“Interferon and
Interferon Inducers”第２版第135頁、1973
年〕により測定する。1 Interferon-like substance induction experiment (a) Animals used ddY mice, male, 10 weeks old, body weight around 40 g, 4 animals per group (b) Antiviral agent according to the present invention, dosage and route of administration Antiviral agent as described above Dosage of injection solution described in the section ``Methods'' 5 ml/Kg once each Administration route Intraperitoneal (ip), subcutaneous injection (sc), and intravenous (iv) (c) Experimental method Mice were divided into 4 groups, one of which was This group is used as a control, and for each of the other three groups, the preparation of the present invention is administered by injection according to the administration route, and 20 hours later, blood is collected from each mouse including the control. The interferon-like activity of the separated serum was measured using Finter.
NB) etc. method [The Assay and
Standardization of Interferon and
Interferon Inducers“Interferon and
Interferon Inducers” 2nd edition, p. 135, 1973
year].
(d) 実験結果
実験結果は下記の通りであり、本発明によ
る抗ウイルス剤は3.3〜４倍程度の活性上昇
をもたらすことが認められた。 (d) Experimental Results The experimental results are as follows, and it was found that the antiviral agent according to the present invention increased the activity by about 3.3 to 4 times.
血清希釈率
対 照 20
i.p. 80
s.c. 60
i.v. 60
２ 抗癌作用実験
ICR系マウス（１群10匹）にEhrlich腹水腫
瘍５×104セル／0.25mlを移植する。移植後24
時間後から本発明製剤（前記「使用法」の項に
記載の注射液）を１日につき１回10日間に亘り
腹腔内注射により投与した処105.9％の延命が
認められた。 Serum dilution rate control 20 ip 80 sc 60 iv 60 2 Anticancer effect experiment Ehrlich ascites tumor 5×10 4 cells/0.25 ml are transplanted into ICR mice (10 mice per group). 24 days after transplantation
After that time, the preparation of the present invention (the injection solution described in the above "How to use" section) was administered by intraperitoneal injection once a day for 10 days, and survival was prolonged by 105.9%.
３ 毒性試験
本発明による抗ウイルス剤に関し急性毒性を
試験した処次の結果が得られた（LD50ml／
Kg）。3. Toxicity test The following results were obtained when the antiviral agent according to the present invention was tested for acute toxicity (LD 50 ml/
Kg).
経 口 皮 下 腹 腔
マウス（雄） 107.5 112.0 108.0
ラツト（雄） 87.5 120.0 59.0
本発明による抗ウイルス剤の注射目的用製剤
の臨床的使用方法を示せば次の通りである。 Oral Subcutaneous Peritoneal cavity Mouse (male) 107.5 112.0 108.0 Rat (male) 87.5 120.0 59.0 The clinical use method of the injectable antiviral agent preparation according to the present invention is as follows.
(a) 予備試験
皮内針付ツベルクリン注射器を用いて膨疹
直径が約４mmとなるように皮下注射し（投与
量約0.02ml）、投与48時間後に発赤の径を測
定し20〜30mm以下であれば使用可能と判定す
る。 (a) Preliminary test Inject the wheal subcutaneously using a tuberculin syringe with an intradermal needle so that the diameter of the wheal is approximately 4 mm (dosage amount approximately 0.02 ml), and measure the diameter of the redness 48 hours after administration. If so, it is determined that it can be used.
(b) 投与方法
通常１日１回以下とし、投与量は成人に関
し0.3mlより開始し0.5ml、0.7ml、1.0mlの順
に増量する。その後の維持量としては１mlと
することが好ましい。 (b) Administration method: Normally, the dose should be no more than once a day, and the dose for adults should start from 0.3ml and increase in the order of 0.5ml, 0.7ml, and 1.0ml. The subsequent maintenance amount is preferably 1 ml.
Claims (1)
と、カタルナイセリアと、四連球菌と、緑膿菌
と、肺炎桿菌と、インフルエンザ菌の死菌体混合
物を有効成分として含有していることを特徴とす
る、抗ウイルス剤。 ２ 特許請求の範囲第１項記載の抗ウイルス剤に
於て、溶液１ml中に 肺炎球菌 50×106個と、 溶血連鎖球菌 40×106個と、 ブドウ球菌 500×106個と、 カタルナイセリア 60×106個と、 四連球菌 20×106個と、 緑膿菌 250×106個と、 肺炎桿菌 40×106個と、 インフルエンザ菌 40×106個 の死菌体と、防腐剤としてのフエノール４mgとを
含有していることを特徴とする、注射目的用抗ウ
イルス剤。[Scope of Claims] 1 Contains a mixture of dead bacterial bodies of Streptococcus pneumoniae, Streptococcus hemolyticus, Staphylococcus catarrhalis, Tetrastreptococcus, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Haemophilus influenzae as an active ingredient An antiviral agent characterized by: 2. In the antiviral agent according to claim 1, 1 ml of solution contains 50 x 10 6 pieces of pneumococcus, 40 x 10 6 pieces of streptococcus hemolyticus, 500 x 10 6 pieces of staphylococcus, and 500 x 10 6 pieces of staphylococcus, and S. catarrh. 6 Neisseria 60× 10 cells, 6 TetraStreptococcus 20×10 cells, 6 Pseudomonas aeruginosa 250×10 cells , 6 Klebsiella pneumoniae cells 40 ×10 cells, and 6 dead bacterial bodies of Haemophilus influenzae 40×10 cells. An antiviral agent for injection, characterized in that it contains 4 mg of phenol as a preservative.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP873080A JPS56108716A (en) | 1980-01-30 | 1980-01-30 | Antiviral agent containing different kind dead cell mixture as effective component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP873080A JPS56108716A (en) | 1980-01-30 | 1980-01-30 | Antiviral agent containing different kind dead cell mixture as effective component |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS56108716A JPS56108716A (en) | 1981-08-28 |
| JPS6234725B2 true JPS6234725B2 (en) | 1987-07-28 |
Family
ID=11701062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP873080A Granted JPS56108716A (en) | 1980-01-30 | 1980-01-30 | Antiviral agent containing different kind dead cell mixture as effective component |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS56108716A (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19916085A1 (en) * | 1998-10-28 | 2000-05-04 | Sonntag Hans Guenther | Antiviral agent, e.g. for treating HIV infections, comprising autovaccine obtained by heating blood containing viruses and antigens with protein crosslinking agent |
| US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| US8501198B2 (en) | 2004-06-07 | 2013-08-06 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| EP1765391B1 (en) * | 2004-06-07 | 2013-03-06 | Qu Biologics Inc | Bacterial compositions for the treatment of cancer |
| US8980279B2 (en) | 2010-07-26 | 2015-03-17 | Qu Biologics | Personalized site-specific immunomodulation |
| KR102157718B1 (en) | 2010-07-26 | 2020-09-18 | 큐 바이올로직스 인코포레이티드 | Immunogenic anti-inflammatory compositions |
| AU2015252726B2 (en) | 2014-05-02 | 2020-12-24 | Qu Biologics Inc. | Anti-microbial immunomodulation |
-
1980
- 1980-01-30 JP JP873080A patent/JPS56108716A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS56108716A (en) | 1981-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fishman | Antibody formation in vitro | |
| KR960003377B1 (en) | Improved interferon therapy | |
| Storb et al. | Treatment of established human graft-versus-host disease by antithymocyte globulin | |
| Thongthai et al. | Studies on the virulence of Neisseria gonorrhoeae I. relation of colonial morphology and resistance to phagocytosis by polymorphonuclear leukocytes | |
| Spink et al. | Experimental studies on the significance of endotoxin in the pathogenesis of brucellosis | |
| KR960000395B1 (en) | Thrombocytopenia treating agent | |
| Miller et al. | Streptomycin resistance of gonococci and meningococci | |
| EP0173241B1 (en) | Vaccines for the treatment of urinary tract infections | |
| US20220267419A1 (en) | Human Immunoglobulin Against Methicillin-Resistant Staphylococcus Aureus, Preparation Method Therefor, And Use Thereof | |
| Snell et al. | Interactions of gram-negative bacterial endotoxin with rabbit blood in vitro | |
| JPS6234725B2 (en) | ||
| Alston et al. | Action of Penicillin on Leptospira | |
| Elias et al. | Blood, urine and fecal levels of streptomycin in the treatment of human infections of E. typhosa | |
| Jariwalla et al. | Infective endocarditis complicating psittacosis: response to rifampicin. | |
| US4472378A (en) | Live vaccine for the prevention of salmonellosis in water fowl, a process for making and applying the same | |
| Schwab et al. | Production of generalized Shwartzman reaction with group A streptococcal factors. | |
| KR0169982B1 (en) | Drug for the treatment of dermatitis | |
| CN101618213B (en) | Combined attenuated live vaccine for measles, mumps and encephalitis B and preparation method thereof | |
| Hobby et al. | An evaluation of chemotherapeutic agents in the control of experimental infections due to Mycobacterium leprae murium | |
| EP1609473A1 (en) | Use of acetyl-d-aminoglycosamine in treatment of local lesions and systematic symptoms related to infections of virus or bacteria | |
| JPS5946493B2 (en) | Antitumor agent containing a mixture of different types of dead bacteria as an active ingredient | |
| Foley et al. | The effect of stilbestrol on experimental streptococcal infection in mice | |
| US3197373A (en) | Immunological agent | |
| Miller et al. | Studies on the action of penicillin: VI. Further observations on the development of penicillin resistance by Meningococcus in vitro | |
| SU997599A3 (en) | Process for preparing heterovaccine for treating trichomonas syndrome |